sustainable Ryan. and I business leadership a growth. excellence, develop initiate strength designed with manufacturing financial the last Recro to joining in Recro Thanks, to Upon December, through and worked build strategy brand
of the our Over has our great last each X four strategy. with months, strides the team prongs made of
a clinical our as are programs As expanding and our our on leadership transfers and for as well inorganic reminder, support restructuring the validations. and financial projects, stage technology high operational strengthening better expanding order organization to augmenting diversifying and Recro's our in customer while facilities to and value and continuing upgrade growth, position capabilities expansion organic both of commercial support they base,
beginning successes quarter, the will with build achievements team point, the quarter I to to each point the by our company's and the customer our During area first our of address our in growing base. of strategy commitment second on continued
strengthen the to customer, as new Ensysce reduce During quarter our base, customer the Pharmaceuticals, with a Biosciences Astex for continued their colleagues diversify line sustainable and towards top I'd as progress and my unnamed portfolio of second and new past for projects expand during of our our profitability. we concentration make the addition Recro margins, all successes quarter. both like risk, well to acknowledge
a During significantly quarter, second successful oversubscribed position, the our also proceeds raised May offering $XX.X million. of net closing public that underwritten in financial the of with strengthened we
reduced and two debt stated $XX through XXXX and delevered a credit addition from December executed which company's in of facility, outstanding the successfully XXXX, of of million rate Recro balance February our were sheet total to In interest. amendments our
$X.X Through these interest $X.X strengthening amendments growth. in both and XXXX. inorganic approximately these organic result will second towards million of our strategic approximately expect million and and in best cash We our of position made year for financial XXXX have goal support full savings to significant we progress achievements, steps
The to leadership as third objective of as our organization. our operational well our is strategy augment restructure
our As you team, and markets Northern representatives addition representatives, may as critical members Boston Southern in as or business reach including business the in for California, Clinical regional announced sales life bolstering Midwest. recall, last of company's the CTS, the development Services quarter, six well Trial new the the to company science and
now is of XX global With professionals executive these sales development Recro's team by experienced time comprised marketing long Hirschman. Bill additions business led and
position our creating global and a running operations environmental, with quarter, until food operational growth an business. equity manner. number with well Raether that key a acquisition diversity, In be the resource Laura and and and Laura execution and short appointment leadership team a Europe, the appointments Ph.D. She and responsibility XX contribute talent is was biopharma, global Recro's doing and and key Patheon, development of at President branding, included recently Bio accounts has in approximately and of to Directors. new focus L. on leadership organization. Vice was member the executive solutions sustainable device India, achieve company’s industries, culture the worked the Erica served arm the success of and CDMO advancing led strategies high -- biotech future of acquisition President pharmaceutical as a Scientific strategic believe our role, advanced the on Vice and and and its Human with enterprise inclusion relation in and people, with given of Japan Services, U.S. responsible in Solae, will Recro leadership in by President Erica leader appointment of engagement, will profitability, Pharmaceuticals Thermo a Board operates Laura as this commitment member end, and the she strategies Ajinomoto for critical, as role with for leading medical planning, culture. as objectives to market the the DSM employment this advancing of years CDMO long-term the and stands governance. employee Resources and global teams which a biopharma served Fischer President Recro within at employee goals management, and its wide-ranging of drive as ESG and global company's as towards made teams track culture inaugural business most as innovative activities. of Recro to global a focusing of role, at division the announced second related ESG, services Vice me efforts and performance, of subsequent of XXXX. announced a company's and In June people to which that to team X,XXX operational of experience significantly This sustainable an global end-to-end U.S additional In companies. achieving CDMO individuals U.S. strategic so management, DuPont. senior mindset July, of we To initiatives, Erica In social recently human performance the Co., Ajinomoto and Pharma the executing goals. developing leadership including a employee commercial Patheon, Prior industry and change Her well of she offering During of employs experienced her record aligned focus that Parks,
organization strides members Erica of and new believe towards and our we appointments additions Parks, the future. Raether, great we have of organization With and these new expect to development operations third we the technical the goal team and each teams, leadership significant to enhancing of our in business make made restructuring of contributions our our Laura
address this to and value clinical fourth our programs commercial like facilities to area and end, capabilities blister expanding capabilities offerings. Recro, technology projects, stage pharmaceuticals. and growing the I upgrade today, packaging of services, is expanded among added continuing sachet and clinical for of and trial which June, Recro capabilities are To while it support validations. Finally, the would CTS announced the strategic expand for company's focus that transfers to CTS in high clinical-scale trial clinical Included newly the clinical
services We are to earning services a more very efficient incorporate they sales which and new clients support for revenue. a Further, rapid to offering provide to as shorter our allow clients. these attract happy existing these and the new and cycles of with contribution
declaration successful or following during a a country. the required Qualified first new biotechnology the the QP’s relationship to company. has clinical European using Based in in company a CTS the for or non-EU of process. is product for been the allowing to materials customers. Europe for Union A QP clinical In closing, CTS manufactured these a Europe-based the I QP in trial QP of offerings organization seeking the X to last Recro pharmaceutical with the addition Recro, support any have time, believe capabilities Person In and a quarter, EU, agreed established review its for drug successfully its on validating audit, the of conduct months it efforts trial particular, QX, for represent clients results Recro’s the release can that in
newly and results. implemented seen early and impressive We have continue to our execute strategy
achieving bringing and grow, experience growth. to talent Today sales organization. we to an critical have well and diverse we Our progress more continue to a as CDMO towards exceptional team stronger, sustainable other and superb as continues base, building profitability customer make
and has Our financing with outstanding growth finally, company's a make both efforts end status restructuring the the company's to of and credit business, our reduction inorganic enhancing to through organic And in drive competencies, and of the improved the completion will which progress of continue financial significantly successful of since facility. we fiscal and continued the to critical capabilities be XXXX activities. our
As conveyed improvements to I'm quarters. accomplishments more I Recro's coming achievements I made during proud I on and This value XXXX, up We my given can prepared believe creation for significant Recro in thrilled market there of have look many opportunity remarks for our to call and the appreciation reporting cap ahead. with today. open performance hope continue the team. that is Operator? the concludes today, a for in questions. we've forward now the I'm of